Cancer Letters
Volume 291, Issue 1 , Pages 67-75 , 1 May 2010

Selective targeting of HPV-16 E6/E7 in cervical cancer cells with a potent oncolytic adenovirus and its enhanced effect with radiotherapy in vitro and vivo

  • Wei Wang

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • These authors contributed equally to this manuscript.
    • ,
  • Ni Sima

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, PR China
    • These authors contributed equally to this manuscript.
    • ,
  • Debo Kong

      Affiliations

    • The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, PR China
    • ,
  • Aiyue Luo

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • ,
  • Qinglei Gao

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • ,
  • Shujie Liao

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • ,
  • Wei Li

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • ,
  • Lingfei Han

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • ,
  • Juan Wang

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • ,
  • Shixuan Wang

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • ,
  • Yunping Lu

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • ,
  • Daowen Wang

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • ,
  • Gang Xu

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • ,
  • Jianfeng Zhou

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • ,
  • Li Meng

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • Corresponding Author InformationCorresponding authors. Fax: +86 (27) 83662681.
    • ,
  • Ding Ma

      Affiliations

    • Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China
    • Corresponding Author InformationCorresponding authors. Fax: +86 (27) 83662681.

Received 7 September 2009 ,Accepted 30 September 2009.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005;55:74–108
  2. Moore DH. Cervical cancer. Obstet. Gynecol. 2006;107:1152–1161
  3. Petignat P, Roy M. Diagnosis and management of cervical cancer. BMJ. 2007;335:765–768
  4. Cadron I, Van Gorp T, Amant F, Leunen K, Neven P, Vergote I. Chemotherapy for recurrent cervical cancer. Gynecol. Oncol. 2007;107:S113–118
  5. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373–376
  6. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al. A controlled trial of intratumoral ONYX-015 a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 2000;6:879–885
  7. Habib NA, Mitry RR, Sarraf CE, Jiao LR, Havlik R, Nicholls J, et al. Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus. Cancer Gene Ther. 2002;9:414–420
  8. Hay JG, Shapiro N, Sauthoff H, Heitner S, Phupakdi W, Rom WN. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Hum. Gene Ther. 1999;10:579–590
  9. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 2000;6:1134–1139
  10. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19:2–12
  11. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 2000;6:798–806
  12. Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N, et al. CV706 a prostate cancer-specific adenovirus variant in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res. 2001;61:5453–5460
  13. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin. Cancer Res. 2004;10:5299–5312
  14. Yu DC, Working P, Ando D. Selectively replicating oncolytic adenoviruses as cancer therapeutics. Curr. Opin. Mol. Ther. 2002;4:435–443
  15. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J. Natl. Cancer Inst. 1995;87:796–802
  16. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Engl. J. Med. 2003;348:518–527
  17. Howley PM. Role of the human papillomaviruses in human cancer. Cancer Res. 1991;51:5019s–5022s
  18. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer. 2002;2:342–350
  19. Steinwaerder DS, Carlson CA, Lieber A. Human papilloma virus E6 and E7 proteins support DNA replication of adenoviruses deleted for the E1A and E1B genes. Mol. Ther. 2001;4:211–216
  20. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Pecorelli S, Parham GP. Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma. Cancer. 1998;83:2346–2352
  21. Tang X, Zhang Q, Nishitani J, Brown J, Shi S, Le AD. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin. Cancer Res. 2007;13:2568–2576
  22. Zhou J, Gao Q, Chen G, Huang X, Lu Y, Li K, et al. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability. Clin. Cancer Res. 2005;11:8431–8440
  23. Ketner G, Boyer J. Isolation, growth, and purification of defective adenovirus deletion mutants. Adenov. Methods Protocols. 1998;25–32
  24. Sima N, Wang W, Kong D, Deng D, Xu Q, Zhou J, et al. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53. Apoptosis. 2008;13:273–281
  25. Sima N, Wang S, Wang W, Kong D, Xu Q, Tian X, et al. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Gynecol. Oncol. 2007;106:299–304
  26. Pelletier AJ, Kunicki T, Quaranta V. Activation of the integrin alpha v beta 3 involves a discrete cation-binding site that regulates conformation. J. Biol. Chem. 1996;271:1364–1370
  27. Zhang WW. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 1999;6:113–138
  28. Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell. 2002;1:325–337
  29. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 2005;12:141–161
  30. Gao Q, Zhou J, Huang X, Chen G, Ye F, Lu Y, et al. Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus. Mol. Ther. 2006;13:928–937
  31. Chen G, Zhou J, Gao Q, Huang X, Li K, Zhuang L, et al. Oncolytic adenovirus-mediated transfer of the antisense chk2 selectively inhibits tumor growth in vitro and in vivo. Cancer Gene Ther. 2006;13:930–939
  32. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998;12:2245–2262
  33. Cam H, Dynlacht BD. Emerging roles for E2F: beyond the G1/S transition and DNA replication. Cancer Cell. 2003;3:311–316
  34. Matsukura T, Koi S, Sugase M. Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology. 1989;172:63–72
  35. Yasmeen A, Bismar TA, Kandouz M, Foulkes WD, Desprez PY, Al Moustafa AE. E6/E7 of HPV type 16 promotes cell invasion and metastasis of human breast cancer cells. Cell Cycle. 2007;6:2038–2042
  36. Bertelsen K, Jakobsen A. Radiotherapy for gynecologic cancer. Curr. Opin. Oncol. 1993;5:885–890
  37. Chen SW, Liang JA, Yang SN, Hung YC, Yeh LS, Shiau AC, et al. Radiation injury to intestine following hysterectomy and adjuvant radiotherapy for cervical cancer. Gynecol. Oncol. 2004;95:208–214
  38. von Eschenbach AC. A vision for the national cancer program in the United States. Nat. Rev. Cancer. 2004;4:820–828
  39. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61:7464–7472
  40. Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res. 2001;61:517–525

PII: S0304-3835(09)00621-1

doi: 10.1016/j.canlet.2009.09.022

Cancer Letters
Volume 291, Issue 1 , Pages 67-75 , 1 May 2010

Article Tools

* Image Usage & Resolution